Cipher Pharmaceuticals Valuation
| CPHRFDelisted Stock | USD 2.57 0.00 0.00% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Cipher Pharmaceuticals shows a prevailing Real Value of $2.44 per share. The current price of the firm is $2.57. Our model approximates the value of Cipher Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 46.13 M, profit margin of 0.45 %, and Return On Equity of 0.24 as well as examining its technical indicators and probability of bankruptcy. . In general, most investors favor locking in undervalued instruments and disposing overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that Cipher Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Cipher Pharmaceuticals is based on 3 months time horizon. Increasing Cipher Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cipher otc stock is determined by what a typical buyer is willing to pay for full or partial control of Cipher Pharmaceuticals. Since Cipher Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cipher OTC Stock. However, Cipher Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.57 | Real 2.44 | Hype 2.57 | Naive 2.44 |
The real value of Cipher OTC Stock, also known as its intrinsic value, is the underlying worth of Cipher Pharmaceuticals OTC Stock, which is reflected in its stock price. It is based on Cipher Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cipher Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cipher Pharmaceuticals helps investors to forecast how Cipher otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cipher Pharmaceuticals more accurately as focusing exclusively on Cipher Pharmaceuticals' fundamentals will not take into account other important factors: Cipher Pharmaceuticals Total Value Analysis
Cipher Pharmaceuticals is currently projected to have takeover price of 46.13 M with market capitalization of 64.32 M, debt of 507 K, and cash on hands of 24.19 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cipher Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
46.13 M | 64.32 M | 507 K | 24.19 M |
Cipher Pharmaceuticals Investor Information
About 44.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.63. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cipher Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Cipher Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Cipher Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Cipher Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cipher Pharmaceuticals has an asset utilization ratio of 42.48 percent. This implies that the OTC Stock is making $0.42 for each dollar of assets. An increasing asset utilization means that Cipher Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Cipher Pharmaceuticals Ownership Allocation
Cipher Pharmaceuticals holds a total of 25.12 Million outstanding shares. Cipher Pharmaceuticals retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cipher Pharmaceuticals Profitability Analysis
The company reported the revenue of 21.94 M. Net Income was 7.76 M with profit before overhead, payroll, taxes, and interest of 18.26 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cipher Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cipher Pharmaceuticals and how it compares across the competition.
About Cipher Pharmaceuticals Valuation
The otc valuation mechanism determines Cipher Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Cipher Pharmaceuticals. We calculate exposure to Cipher Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cipher Pharmaceuticals's related companies.Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada. Companhia Siderurgica is traded on OTC Exchange in the United States.
8 Steps to conduct Cipher Pharmaceuticals' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Cipher Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cipher Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Cipher Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Cipher Pharmaceuticals' revenue streams: Identify Cipher Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Cipher Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Cipher Pharmaceuticals' growth potential: Evaluate Cipher Pharmaceuticals' management, business model, and growth potential.
- Determine Cipher Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cipher Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Cipher Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cipher Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 25.9 M | |
| Quarterly Earnings Growth Y O Y | 2.333 | |
| Forward Price Earnings | 9.311 | |
| Retained Earnings | 25.2 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Cipher OTC Stock
If you are still planning to invest in Cipher Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cipher Pharmaceuticals' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |